Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomised, Phase-I, Multi-Centre Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men With Newly Diagnosed Prostate Cancer (ASCERTAIN)

NCT05938270 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05938270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05938270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomised, Phase-I, Multi-Centre Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men With Newly Diagnosed Prostate Cancer (ASCERTAIN)
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
September 21, 2023
Completion date
June 15, 2026
Enrollment
113 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer